News

EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria
Telomir Pharmaceuticals Inc. (NASDAQ:TELO) on Wednesday announced new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from ...
Green Bay Press-Gazette15d
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - Green Bay Press ...
The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years.
Sacramento Bee15d
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - The Sacramento Bee
The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not ...
Benzinga.com15d
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria
Telomir-1 improved survival in progeria cells and normalized ROS levels under oxidative stress. The candidate reduced mitochondrial calcium overload, restoring cell energy balance. Geopolitical ...